Br J Cancer. 2010 Sep 7;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10.

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Source

Department of Medicine, Division of Oncology, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.

Abstract

Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that tumour response in this setting may predict long-term outcome of patients on adjuvant endocrine therapy, which argues for its broader application in treating hormone receptor-positive disease. From the research perspective, neoadjuvant endocrine therapy provides a unique opportunity for studies of endocrine responsiveness and the development of novel therapeutic agents.

PMID:: 20700118; [PubMed - indexed for MEDLINE]
PMCID:: PMC2966629

Free PMC Article

Images from this publication.See all images (1)Free text

LinkOut - more resources

Full Text Sources

Medical

Breast Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Click here to read article using PubReader

Related citations in PubMed

Review Neoadjuvant endocrine therapy for breast cancer. [Surg Oncol Clin N Am. 2010]
Review Neoadjuvant endocrine therapy for breast cancer.
Chawla JS, Ma CX, Ellis MJ. Surg Oncol Clin N Am. 2010 Jul; 19(3):627-38.
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. [Med Oncol. 2009]
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J. Med Oncol. 2009 Dec; 26(4):480-90. Epub 2009 Jan 7.
Review Factors predictive of response to hormone therapy in breast cancer. [Tumori. 2008]
Review Factors predictive of response to hormone therapy in breast cancer.
Rastelli F, Crispino S. Tumori. 2008 May-Jun; 94(3):370-83.
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. [J Natl Cancer Inst Monogr. 2011]
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, et al. J Natl Cancer Inst Monogr. 2011; 2011(43):120-3.
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. [Eur J Cancer. 2006]
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, et al. Eur J Cancer. 2006 Mar; 42(5):629-35. Epub 2006 Feb 7.

See reviews... See all...

Cited by 6 PubMed Central articles

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. [Radiol Oncol. 2013]
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.
Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M, Massarut S, Veronesi A. Radiol Oncol. 2013 Mar; 47(1):57-62. Epub 2013 Feb 1.
Whole-genome analysis informs breast cancer response to aromatase inhibition. [Nature. 2012]
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. Nature. 2012 Jun 10; 486(7403):353-60. Epub 2012 Jun 10.
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. [Breast Cancer Res. 2012]
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, et al. Breast Cancer Res. 2012 Jan 20; 14(1):R16. Epub 2012 Jan 20.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a...
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
Br J Cancer. 2010 Sep 7 ;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information